New developments in the treatment of gastric carcinoma

Publisher Website
Google Scholar
Abstract
Surgery is the treatment of choice in localized gastric carcinoma. Despite the availability of extended surgical procedures (e.g., gastrectomy, lymphadenec-tomy), the majority of patients with gastric cancer fail surgical treatment. This applies especially to patients with stage III and IV disease who represent more than two thirds of the cases at diagnosis. The 5-year survival rate in stage III disease is less than 15%; in stage IV disease, long-term survival is rare [1]. In addition, the median survival time of patients with advanced gastric carcinoma is short. After potentially curative resection of localized stage III/IV gastric carcinomas, the median survival is approximately 8 months, and after palliative resection, 4–6 months [1]. For patients with unresectable tumors, the outlook is dismal, with median survival being only 4 months [2]. Therefore, other treatment modalities, especially systemic chemotherapy, have been investigated intensively. Keywords Gastric Cancer Clin Oncol Advanced Gastric Cancer Remission Rate Peritoneal Carcinomatosis These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.